Chidambaram Ramasamy
Farmington, CTNPI 1275187684
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Reporting peaked in 2022 at $608 and has fallen 91.9% since, to $49 in 2024.
Across 107 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$626
- E.r. Squibb & Sons, L.L.C.$291
- AbbVie$234
- Gilead$226
- Pfizer$196
- Takeda Pharmaceuticals U.S.A., Inc.$125
- plus $486 from 11 others
What the payments were for
- Food & beverage$2,184100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 31 | $626 |
| E.r. Squibb & Sons, L.L.C. | 18 | $291 |
| AbbVie(2 entities) | 9 | $234 |
| Gilead | 11 | $226 |
| Pfizer | 14 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $125 |
| Boehringer Ingelheim | 8 | $122 |
| Alcresta Therapeutics, Inc. | 2 | $116 |
| Bayer | 3 | $69 |
| Viiv Healthcare Company | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Incyte Corporation | 1 | $18 |
| GSK | 1 | $12 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.